COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
ugichem GmbH develops an antisense drug platform and preclinical Ugimer therapeutics targeting immune-mediated inflammatory diseases, primarily rheumatoid arthritis.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor